安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Tardive Dyskinesia - StatPearls - NCBI Bookshelf
Tardive dyskinesia is most common in people with schizophrenia and bipolar patients treated with antipsychotic medications but can occur in the setting of any disorder In addition, the medications that precipitate tardive dyskinesia can also induce Parkinsonian symptoms
- Tardive Dyskinesia (TD): Definition, Symptoms, Causes . . . - WebMD
Tardive dyskinesia (TD) is a side effect of some medicines, usually antipsychotics, and causes involuntary muscle movements Have a mental health condition, such as schizophrenia or bipolar
- Tardive dyskinesia in schizophrenia | The British Journal of . . .
Tardive dyskinesia in schizophrenia - Volume 203 Issue 1 Sarró et al Reference Sarró, Pomarol-Clotet, Canales-Rodríguez, Salvador, Gomar and Ortiz-Gil 1 report that in patients with schizophrenia, tardive dyskinesia is associated with widespread deficits in the amount of cerebral grey matter, most prominently in the basal ganglia and thalamus, but also in frontal and temporal cortex
- Tardive Dyskinesia (TD): What It Is, Symptoms Treatment
What drugs cause tardive dyskinesia? Tardive dyskinesia can develop due to exposure to the following medications: Antipsychotic medications (neuroleptics) Metoclopramide or other anti-nausea medications Certain antidepressants In rare cases, TD may also develop due to other medications: Lithium Antiseizure medications
- Tardive dyskinesia - Wikipedia
Tardive dyskinesia (TD) is an iatrogenic disorder that results in involuntary repetitive body with diseases of chronic psychosis such as schizophrenia, this
- Treatment Recommendations for Tardive Dyskinesia - PMC
Kinon BJ, Jeste DV, Kollack-Walker S, et al Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods Prog Neuro-Psychopharmacol Biol Psychiatry 2004;28(6):985–996 [Google Scholar] 47 Brar JS, Parepally H, Chalasani L, et al
- Tardive Dyskinesia: Treat Functional Impairment, Not the AIMS . . .
The American Psychiatric Association updated their practice guidelines for the treatment of schizophrenia in 2020 and recommended “that patients who have moderate to severe or disabling tardive dyskinesia associated with antipsychotic therapy be treated with a reversible inhibitor of the vesicular monoamine transporter 2 ” 6
- Schizophrenia and Tardive Dyskinesia (TD)
Instead, tardive dyskinesia results from a common treatment for schizophrenia and other psychotic disorders: medication Most cases of TD are related to the extended use of antipsychotic medications that block dopamine receptors in the central nervous system
|
|
|